Peng Li

Dr. Peng Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Cancer Medicine
Verified
Journal Article
Open access
LHLu Han
Lu Han
FGFangming Gong
Fangming Gong
XWXuxiaochen Wu
Xuxiaochen Wu
WTWanxiangfu Tang
Wanxiangfu Tang
HBHua Bao
Hua Bao
PLPeng Li
Peng Li
Introduction: The PKHD1 (Polycystic Kidney and Hepatic Disease 1) gene is essential for producing fibrocystin or polyductin, which is crucial in various cellular functions. Mutations in PKHD1 have been found to be involved in the development and progression of colorectal cancer (CRC). Along with APC, TP53, and KRAS, PKHD1 is one of the most frequently mutated genes in CRC. PKHD1 expression is governed by the Wnt/PCP pathway, often dysregulated in CRC. Targeting this pathway, crucial for CRC progression, could unveil potential therapeutic strategies for colon cancer treatment.Methods: This study examined an in‐house dataset of 3702 colon cancer samples, analyzing mutation landscapes, clinical features, tumor mutational burden (TMB), microsatellite instability (MSI), and chromosomal instability (CIN) score. For the survival analysis of PKHD1 patients, survival data of 436 colon adenocarcinoma samples were obtained from TCGA dataset. Additionally, 433 samples from TCGA with RNA‐seq data were used for the assessment of immune cell infiltration and gene set enrichment analysis.Results: Polycystic Kidney and Hepatic Disease 1 mutation was detected in 424 colon cancer patients from our in‐house cohort and was associated with increased TMB, higher MSI, and lower CIN score. Importantly, within the TCGA dataset, PKHD1 mutations were identified as an independent prognostic factor, not merely correlated with established prognostic biomarkers, and were associated with poorer overall survival outcomes. In terms of immune response, these mutations correlated with increased enrichment scores for 12 immune cell types, including B cell plasma, macrophages, and naive CD4+ T cells. Additionally, interferon alpha and interferon‐gamma gene sets were significantly down‐regulated in patients with PKHD1 mutations (FDA q‐value < 0.1).Conclusions: Overall, these findings suggest that PKHD1 may be a potential biomarker for the prognosis of colon cancer and provide some insight for personalized immunotherapy.

14 July 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XQXiaoyuan Qiu
Xiaoyuan Qiu
RLRuiqiang Li
Ruiqiang Li
GXGengchen Xie
Gengchen Xie
NNNing Ning
Ning Ning
ZWZhenjun Wang
Zhenjun Wang
GLGuole Lin
Guole Lin
Background: Colorectal cancer (CRC) ranks as the third most common cancer globally, with significant postoperative recurrence and metastasis rates. The heterogeneity of CRC presents challenges in the selection of adjuvant chemotherapy regimens, highlighting the need for personalized treatment strategies. The development of in vitro models for drug sensitivity testing, including a novel patient-derived tumor-like cell cluster (PTC) model, offers a potential solution for predicting drug efficacy and guiding treatment. Methods and design: This multicenter randomized controlled trial (RCT) aims to evaluate the consistency between the in vitro PTC drug sensitivity test results with whole exome sequencing and the clinical prognosis of CRC patients. The study will involve 200 patients who will be randomly assigned to receive either PTC-guided adjuvant chemotherapy or traditional chemotherapy. The primary endpoint is the 3-year disease-free survival rate (3yDFS), with secondary endpoints including the consistency between test results and clinical outcomes and the prognostic value of gene mutations and other biomarkers. Discussion: This study represents a significant step toward precision medicine in CRC treatment by integrating PTC technology with whole-exome sequencing. These findings could provide valuable insights into personalized treatment approaches, potentially improving the clinical outcomes of patients with CRC. Trial registration: ClinicalTrials.gov: NCT05424692. Registered on June 21, 2022.

23 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
WWWenchen Wang
Wenchen Wang
QMQingyu Meng
Qingyu Meng
YCYiping Cheng
Yiping Cheng
YHYalin Han
Yalin Han
YXYonggan Xue
Yonggan Xue
JBJIA baoqing
JIA baoqing
Background: Immunodeficiency diseases (IDDs) are associated with an increased proportion of cancer-related morbidity. However, the relationship between IDDs and malignancy readmissions has not been well described. Understanding this relationship could help us to develop a more reasonable discharge plan in the special tumor population. Methods: Using the Nationwide Readmissions Database, we established a retrospective cohort study that included patients with the 16 most common malignancies, and we defined two groups: non-immunodeficiency diseases (NOIDDs) and IDDs. Results: To identify whether the presence or absence of IDDs was associated with readmission, we identified 603,831 patients with malignancies at their time of readmission in which 0.8% had IDDs and in which readmission occurred in 47.3%. Compared with NOIDDs, patients with IDDs had a higher risk of 30-day (hazard ratio (HR) of 1.32; 95% CI of 1.25–1.40), 90-day (HR of 1.27; 95% CI of 1.21–1.34) and 180-day readmission (HR of 1.28; 95% CI of 1.22–1.35). More than one third (37.9%) of patients with IDDs had readmissions that occurred within 30 days and most (82.4%) of them were UPRs. An IDD was an independent risk factor for readmission in patients with colorectal cancer (HR of 1.32; 95% CI of 1.01–1.72), lung cancer (HR of 1.23; 95% CI of 1.02–1.48), non-Hodgkin’s lymphoma (NHL) (HR of 1.16; 95% CI of 1.04–1.28), prostate cancer (HR of 1.45; 95% CI of 1.07–1.96) or stomach cancer (HR of 2.34; 95% CI of 1.33–4.14). Anemia (44.2%), bacterial infections (28.6%) and pneumonia (13.9%) were the 30-day UPR causes in these populations. (4) Conclusions: IDDs were independently associated with higher readmission risks for some malignant tumors. Strategies should be considered to prevent the causes of readmission as a post discharge plan.